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OBJECTIVES:
The primary aim was to compare short-, mid-, and long-term subjective treatment success in women undergoing MUS for stress urinary incontinence (SUI).
MATERIALS AND METHODS:
Women undergoing a primary MUS between 2001 and 2009 were identified by CPT code. Eligible patients were mailed the Urinary Distress Inventory (UDI-6), Pelvic Floor Impact Questionnaire (PFIQ-7), Patient Global Impression of Improvement (PGI-I), and Patient Satisfaction Questionnaire (PSQ). Patients in the long-term cohort were asked whether to undergo a MUS procedure again. Follow-up intervals were categorized as short-term ( 36 months), mid-term (36-70 months), and longterm (119 -200 months). Treatment success was defined as responses of "not at all" or "somewhat" to both SUI subscales on the UDI-6. Chi-squared tests for categorical variables, and analysis of variance (ANOVA) or Kruskal-Wallis for continuous variables were utilized. Logistic regression was used to examine the association between follow-up group and subjective treatment success, between shortand combined mid-and long-term follow-up groups after adjustment for covariates. RESULTS: Of N¼896 respondents, 361 were assessed short-term (mean: 23.3AE7.2 months), 251 mid-term (49.8AE9.1 months), and 284 in long-term (147.9AE20.6 months) follow-up. Differences were significant for age (short: 60.9AE11.6, mid: 60.3 AE 12.5, long: 58.4AE10.5, p¼0.03), smoking status, prior prolapse surgery, and perioperative vaginal estrogen use (all p<0.05). Treatment success differed among groups: 75.4% in the short-, 62.3% mid-, and 67.0% long-term groups, p<0.01. Logistic regression showed that women with mid-or long-term follow up were nearly half as likely as their short-term counterparts to report subjective treatment success, adjusted Odds Ratio OR 0.51, 95% Confidence Interval CI, 0.36, 0.74. Median UDI-6 and PFIQ-7 scores revealed significant differences among short-, mid-and long-term follow-up, all p<0.01 (Table) . Findings were similar for the PGI-I, p<0.01. Patient satisfaction was similar: "completely" and "somewhat satisfied" in 83.3% short-, 76.6% mid-, 78.2% long-term (p ¼ 0.09) follow-up. In the long-term group, 73.1% reported they would undergo a MUS again. CONCLUSION: Subjective treatment success, post-operative symptom severity, and condition-specific QOL differed among short-, mid-, and long-term groups, with higher success and improved symptoms Oral Posters in the short-term group in women undergoing MUS. There is a drop to mid-and long-term success which is stable and sustained to 12 years; high satisfaction was sustained across the follow-up groups. Given the paucity of data on long-term outcomes of MUS, this information is valuable and informs to patient expectations.
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14 Defining continence following surgical treatment of stress urinary incontinence (SUI) 
OBJECTIVES:
To correlate patient perception of improvement and treatment success with various definitions of continence following surgical repair of SUI in order to identify the optimal definition of continence. MATERIALS AND METHODS: Thirteen continence definitions of success versus failure were defined from items in a self-reported, validated questionnaire completed by participants at 6, 12, and 24 months following surgery (N¼104, 97, and 86, respectively) in a randomized trial comparing Burch retropubic urethroplexy with retropubic midurethral sling. The questionnaires included the ICIQ, items from the stress incontinence subscale of the MESA Questionnaire, the UDI-6, and OABSS. Treatment success (0¼not at all successful, 10¼very successful) and symptom improvement (0¼much worse, 10¼much better) were rated by the patient using a 0-10 scale. For each scale, the ratings were compared between patients categorized as success versus failure by each continence definition and the magnitude of the standardized mean difference was quantified using Cohen's d. RESULTS: Continence rates at 6 months for the different definitions ranged from 29.3% (patient perception of bladder condition "perfect"), 50% (composite continence definition: negative CST, ICIQ¼0 and no retreatment), 76% (ICIQ score 5), and 79% (negative CST). At 6-months, a definition of ICIQ score 5 yielded the greatest Cohen's d value for patient perception of symptom improvement (-13.5 ; mean ratings of 9.7 vs. 4.6). In comparison, the Cohen's d values for definitions based on a) negative CST or b) the strict composite definition were considerably less at -6.5 and -6.4, respectively (Table1). The three definitions of either (a) ICIQ score 5, (b) ICIQ score 5 with no ("not-at-all" or "somewhat") SUI symptoms on UDI-6, and (c) ICIQ score 5 with no SUI symptoms (never or rarely) on MESA had the highest Cohen's d values for patient perception of symptom improvement at each time point (-13.5, -13.0, and -12.6 at 6 months; -7.2, -7.2, and -8.1 at 12 months; and -7.0, -7.0, -6.4 at 24 months, respectively). Similar results were obtained for these continence definitions when evaluating the patient's perception of treatment success (Table1). CONCLUSION: Continence rates vary drastically based on the definition selected. Success based on ICIQ score 5 appears to best differentiate patients based on their perception of treatment success and symptoms improvement. This finding was consistent across time points, suggesting that stringent definitions may not be optimal for defining patient perception of surgical success.
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